Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003820 · ClinicalTrials.gov registry record · Phase 2
Rituximab in Treating Patients With Hodgkin's Lymphoma
A Phase 2 study of Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma, sponsored by Ranjana Advani.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT00003820: Completed Phase 2 study of Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma, sponsored by Ranjana Advani.
NCT00003820 is a Phase 2 study of Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma that has completed, run by Ranjana Advani. The registered enrollment target is 39 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003820, a Phase 2 study of Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma, has completed, sponsored by Ranjana Advani.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.
Primary Outcome
PFS, assessed as the number of patients 5 years after treatment who are alive and without a ≥ 50% increase from nadir in the sum of the product of the greatest lesion diameters (SPD) of any previously-identified abnormal node, or appearance of any new lesion
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (2)
California
- Stanford University Medical Center - Stanford
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1999-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
What the finished NCT00003820 record still lists
NCT00003820 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00003820 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00003820 about?
NCT00003820 is a clinical study titled "Rituximab in Treating Patients With Hodgkin's Lymphoma". Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.
What is the current status of trial NCT00003820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 1999-01. Estimated completion is 2008-08.
What conditions does trial NCT00003820 study?
This clinical trial studies the following conditions: Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma, Hodgkin Lymphoma (Category).
What interventions are being tested in trial NCT00003820?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00003820?
This trial is sponsored by Ranjana Advani, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003820 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003820's enrollment target sits among peer trials
39 185th of 299 higher than 111 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia